# BPC-157 TB-500: The Wolverine Blend Research Record, Filed and Cited > BPC-157 TB-500 is the two-peptide Wolverine research blend. Each constituent finding, dosing parameter, and FDA 503A access mark filed as its own entry, with the source attached. BPC-157 supplies the cytoprotective, pro-angiogenic leg; TB-500 supplies the actin-binding, cell-migration leg. Every constituent finding is preclinical, single-compound, and cited to its study. The blend itself has no controlled trial. ## The Wolverine blend, filed as two constituents BPC-157 TB-500 is the research-community name for a two-peptide pairing, marketed and discussed as a tissue-repair "stack." It is not a single chemical entity. There is no CAS number for the blend, no standardized ratio, and no approved product anywhere. What exists is two distinct synthetic peptides, each carrying its own deck of preclinical findings, filed side by side. BPC-157 (Body Protection Compound 157) is a 15-amino-acid pentadecapeptide, sequence GEPPPGKPADDAGLV, derived from a partial sequence of a protein isolated from human gastric juice [9]. TB-500 is a synthetic N-acetylated heptapeptide, Ac-LKKTETQ, corresponding to residues 17-23 — the actin-binding motif — of the 43-residue intracellular protein Thymosin Beta-4 [3]. The two were never co-formulated by a manufacturer with a validated specification; the pairing is a construct of the research-peptide market. This site reads the record the way a property portal files listings: each finding gets its own entry, a constituent tag marking which leg of the blend it belongs to, an evidence-tier status, and the citation attached. Color and badge are never the only signal — every entry carries a label word. Browse [BPC-157 and TB-500 research findings](/research), the [BPC-157 and TB-500 dosage in animal models](/dosage), and the [Wolverine legal status and FDA 503A category](/legal-status). ## The Wolverine Peptide Blend: BPC-157 and TB-500 in Combination The Wolverine peptide blend pairs BPC-157 and TB-500 on the rationale that the two peptides cover different stages of tissue repair. BPC-157 is described as a local cytoprotective and pro-angiogenic signal: it up-regulates VEGFR2 and promotes its internalization, with downstream Akt-eNOS activation [2]. TB-500 — through its parent protein Thymosin Beta-4 — is described as a cytoskeletal signal: the LKKTETQ helix binds monomeric G-actin in a 1:1 complex and regulates the actin dynamics that drive cell migration and re-epithelialization [3][4]. Those two mechanisms are largely non-overlapping, which is the entire basis of the "synergy" idea. It is an extrapolation from each peptide's separately characterized biology, not a measured result. No peer-reviewed study has defined a synergistic dose, ratio, or endpoint for the two given together [9]. A reader should treat "BPC-157 plus TB-500 is greater than the sum" as a hypothesis the published literature has not tested. ## Why the Research Community Pairs BPC-157 with TB-500 The case for pairing BPC-157 with TB-500 is mechanistic complementarity. BPC-157's contribution is vascular and local: increased vessel density and faster blood-flow recovery in ischemic rat muscle, with effects blocked when VEGFR2 endocytosis is inhibited [2]. TB-500's contribution, inherited from Thymosin Beta-4, is cytoskeletal: actin sequestration that mobilizes keratinocytes, endothelial cells, and progenitor cells, accelerating wound coverage in animal models [4][5]. The honest caveat is the one the marketing omits. No head-to-head or combination study has demonstrated that the two together outperform either alone, and a 2025 systematic review of BPC-157 covering 36 studies makes no mention of TB-500 or any combination use at all [9]. The pairing rests on two separate, mostly rodent literatures — not on a single study of the blend. ## What the Blend Is Studied For Across the two constituent literatures, the findings cluster in tissue repair. BPC-157 accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional, and microscopic measures [1]. Thymosin Beta-4 — TB-500's parent — increased re-epithelialization, wound contraction, collagen deposition, and angiogenesis in rat wound models [5]. Both are reported to promote angiogenesis, by separate routes [2][7]. Every one of those results is single-compound and almost entirely rodent. None measured the BPC-157 plus TB-500 combination. The deeper reading lives on the [BPC-157 and TB-500 soft-tissue repair research](/soft-tissue-repair) page, which files the wound and re-epithelialization evidence in detail. --- A curated property-portal listing of the BPC-157 TB-500 record — each constituent finding, dose parameter, and FDA 503A access mark filed as its own cited entry, with no clinic, pharmacy, or prescription behind the keyline.